ATAI AtaiBeckley Inc.

CIK 0002081043 11 ready 8-Ks latest July 16, 2026, 7:27 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 11

Latest filing July 16, 2026, 7:27 AM ET

Top materiality 1.00

Event mix other_material ×6 · m_and_a ×2 · earnings ×2

Sentiment 7 pos · 1 neg · 3 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for ATAI

Highest-materiality recent filing

AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share

July 16, 2026, 7:27 AM ET M&A materiality 1.00 positive item 1.01 item 7.01 item 9.01

Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.
CVR milestones: $1.00 for VLS-01 Phase 3 start, $0.50 for BPL-003 US approval/DEA rescheduling, $1.00 for VLS-01 US approval/DEA rescheduling.

Read filing →

July 16, 2026, 7:27 AM ET M&A materiality 1.00 positive item 1.01 item 7.01 item 9.01

AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share

Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.
May 12, 2026, 8:17 AM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026

Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.
March 6, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026

Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.
March 6, 2026, 6:59 PM ET M&A materiality 0.65 negative item 8.01 item 9.01

AtaiBeckley reports pro forma combined net loss of $704M for 2025 after Beckley Psytech acquisition

Pro forma combined net loss attributable to common stockholders $704.3M, or $3.11 per diluted share, for FY 2025.
February 26, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo

EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.
February 19, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01

AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO

Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
January 8, 2026, 6:59 PM ET other material materiality 0.65 positive item 5.02 item 7.01 item 9.01

AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26

BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.

Earnings & guidance

2026-Q1 EPS reported -$0.08 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

7 positive 1 negative 3 neutral

source · ATAI on sec.gov